EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY-NC-ND 4.0

Bempedoic Acid and First and Recurrent Limb Outcomes in Statin-Intolerant Patients With Peripheral Artery Disease: Insights From the CLEAR Outcomes Trial

Marc P Bonaca iD, Mario Enrico Canonico, Na Li iD, William J Sasiela, Steven E Nissen iD, A Michael Lincoff iD, Stephen J Nicholls iD

Circulation · 2026

DOI: 10.1161/circulationaha.125.078469 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Circulation, 2026. Verfasst von Marc P Bonaca und 6 weiteren Autor:innen. Beteiligte Einrichtung: CPC Clinical Research, University of Colorado School of Medicine, Aurora (M.P.B., M.E.C.). Hauptthemen laut MEDLINE: Peripheral Arterial Disease, Fatty Acids, Dicarboxylic Acids, Hydroxymethylglutaryl-CoA Reductase Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Patients with peripheral artery disease (PAD) are at high risk of major adverse limb events (MALE) and major adverse cardiovascular events (MACE). Recently, bempedoic acid was shown to reduce MACE in primary and secondary prevention patients. Whether bempedoic acid reduces the risk of MALE in patients with PAD is unknown. METHODS: CLEAR Outcomes (Cholesterol Lowering via Bempedoic Acid [ETC1002], an ACL-Inhibiting Regimen) randomized 13 970 patients to bempedoic acid 180 mg or placebo from December 22, 2016, to August 14, 2019. The trial primary end point was MACE-4, defined as death resulting from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, or coronary revascularization. A clinical history of PAD was reported by investigators at baseline. Two blinded vascular medicine specialists independently adjudicated MALE, including adverse events indicating worsening PAD symptoms leading to revascularization, chronic limb-threatening ischemia, and acute limb ischemia. Outcomes were assessed as time to first event and total (including recurrent) events with a negative binomial approach. RESULTS: A total of 1624 of the enrolled patients (mean±SD age, 63.9±9.9 years; 915 [56.3%] female) had PAD at baseline. In patients with PAD in the placebo group, 69 (8.3%) had MALE over a median of 40.6 months, with rate of recurrent events of 4.0%/y. Bempedoic acid reduced the risk of MALE by 36% (hazard ratio, 0.64 [95% CI, 0.44–0.93]; P =0.018). Bempedoic acid reduced total MALE by 45% (relative risk, 0.55 [95% CI, 0.35–0.85]; P =0.007). First MACE-4 or MALE was reduced overall by 13% (hazard ratio, 0.87 [95% CI, 0.80–0.95]) with consistent effects with PAD (hazard ratio, 0.82 [95% CI, 0.64–1.04]) and without PAD (hazard ratio, 0.87 [95% CI, 0.79–0.86]; P interaction =NS) but not statistically significant within the PAD subgroup alone. Total MACE-4 or MALE was reduced (relative risk, 0.81 [95% CI, 0.73–0.90]) overall with consistent effects in PAD (relative risk, 0.71 [95% CI, 0.54–0.95]) and without PAD (relative risk, 0.82 [95% CI, 0.73–0.92]; P interaction =NS). CONCLUSIONS: Patients with PAD are at high risk of MALE and MACE. Bempedoic acid reduces both MACE and MALE in patients with atherosclerotic vascular disease, with notable absolute benefits in patients with PAD. These findings support (1) the importance of lowering low-density lipoprotein cholesterol in patients with PAD to reduce overall vascular risk and (2) the benefits of bempedoic acid in this population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Peripheral Arterial DiseaseFatty AcidsDicarboxylic AcidsHydroxymethylglutaryl-CoA Reductase InhibitorsHumansMaleAgedFemaleMiddle AgedTreatment OutcomeRecurrenceDouble-Blind MethodRisk Factors

Stichwörter der Autor:innen

8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acidcardiovascular diseasescholesterol, LDLhypolipidemic agentslipoproteinsperipheral artery disease

Substanzen

Fatty AcidsDicarboxylic Acids8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acidHydroxymethylglutaryl-CoA Reductase Inhibitors

Autor:innen und Institutionen

  • CPC Clinical Research, University of Colorado School of Medicine, Aurora (M.P.B., M.E.C.).
  • Department of Medicine, University of Colorado, Aurora (M.P.B., M.E.C.).
  • Esperion Therapeutics, Inc, Ann Arbor, MI (N.L., W.J.S.).
  • Department of Cardiovascular Medicine and Cleveland Clinic Coordinating Center for Clinical Research (C5Research), Cleveland Clinic, OH (S.E.N., A.M.L.).
  • Victorian Heart Institute, Monash University, Melbourne, Victoria, Australia (S.J.N.).

ORCID-Profile: Marc P Bonaca, Na Li, Steven E Nissen, A Michael Lincoff, Stephen J Nicholls

Zitieren

APA

Bonaca, M. P., Canonico, M. E., Li, N., Sasiela, W. J., Nissen, S. E., Lincoff, A. M., & Nicholls, S. J. (2026). Bempedoic Acid and First and Recurrent Limb Outcomes in Statin-Intolerant Patients With Peripheral Artery Disease: Insights From the CLEAR Outcomes Trial. Circulation. https://doi.org/10.1161/circulationaha.125.078469

Vancouver

Bonaca MP, Canonico ME, Li N, Sasiela WJ, Nissen SE, Lincoff AM, et al. Bempedoic Acid and First and Recurrent Limb Outcomes in Statin-Intolerant Patients With Peripheral Artery Disease: Insights From the CLEAR Outcomes Trial. Circulation. 2026. doi:10.1161/circulationaha.125.078469

BibTeX
@article{Bonaca2026,
  author = {Bonaca, Marc P and Canonico, Mario Enrico and Li, Na and Sasiela, William J and Nissen, Steven E and Lincoff, A Michael and Nicholls, Stephen J},
  title = {Bempedoic Acid and First and Recurrent Limb Outcomes in Statin-Intolerant Patients With Peripheral Artery Disease: Insights From the CLEAR Outcomes Trial},
  journal = {Circulation},
  year = {2026},
  doi = {10.1161/circulationaha.125.078469}
}
Kostenlos starten →